Skip to main content
NATR
NASDAQ Life Sciences

Prescott Group and Phil Frohlich Deploy $2.3M into NATR Following Guidance Cut

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Food & Beverage Stocks · Consumer
Sentiment info
Positive
Importance info
7
Price
$15.77
Mkt Cap
$277.481M
52W Low
$12.973
52W High
$28.14
52W Position info
22% above low
Off High info
44% below high
Rel. Volume info
3.0× avg
Market data snapshot near publication time

NATR sits 22% above its 52-week low of $12.973 on elevated volume (3.0× avg).

Summary

Phil Frohlich and his Prescott Group entities bought $2.3 million of Nature's Sunshine stock in the open market, starting the day of the company's Q2 earnings and guidance cut and continuing through today.


Key Events · Ownership and Investor Activity · NATR

  • 10% Owner Buys $2.3M After Guidance Cut

    Phil Frohlich and his Prescott Group entities purchased 141,389 shares for $2,318,912 in the open market between August 6 and August 10, at prices ranging from $15.64 to $16.75.

  • Buying Began on Earnings Day

    The first purchases were made on August 6, the same day Nature's Sunshine reported Q2 2026 earnings and cut full-year guidance, suggesting the buyer viewed the subsequent price decline as a buying opportunity.

  • Post-Transaction Holdings Reach 1.92M Shares

    Following the purchases, the Prescott Group entities and Frohlich indirectly hold 1,924,486 shares, representing a significant stake in the company.


Analysis · NATR · Life Sciences

Between August 6 and August 10, entities controlled by 10% owner Phil Frohlich acquired $2.3 million of Nature's Sunshine stock on the open market. The buying commenced the very day the company reported Q2 earnings and lowered its full-year outlook, and it persisted through today. While 10% owners are financial investors rather than operators, the timing and scale—representing roughly 0.8% of the company—signal a conviction that the post-earnings selloff was excessive. The purchases were executed at prices ranging from $15.64 to $16.75, near the current $15.77 level.

At the time of this filing, NATR was trading at $15.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $277.5M. The 52-week trading range was $12.97 to $28.14. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NATR - Latest Insights

NATR
Aug 06, 2026, 5:15 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $17.95
Real-time Price: $16.08 info
Change: -$1.87 (-10%) info
Market Cap: $277.481M info
NATR
Aug 06, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.40
Real-time Price: $16.08 info
Change: -$0.320 (-2%) info
Market Cap: $277.481M info
NATR
May 11, 2026, 8:53 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $24.23
Real-time Price: $16.08 info
Change: -$8.15 (-34%) info
Market Cap: $277.481M info
NATR
May 11, 2026, 8:46 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $24.23
Real-time Price: $16.08 info
Change: -$8.15 (-34%) info
Market Cap: $277.481M info
NATR
May 07, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.83
Real-time Price: $16.08 info
Change: -$11.75 (-42%) info
Market Cap: $277.481M info